Keywords
relapsed/refractory Hodgkin´s lymphoma, nivolumab, pembrolizumab, allogeneic transplant
How to Cite
Zerga, M. (2019). Is there any place for the allogeneic transplant in classic Hodgkin´s lymphoma in the check point inhibitors era?. Journal of Hematology, 22(Extraordin), 23–29. Retrieved from https://revistahematologia.com.ar/index.php/Revista/article/view/52
Abstract
Desde la descripción original del Dr. Thomas Hodgkin en 1832, el linfoma de Hodgkin (LH) representa el paradigma del avance constante de la terapia oncológica. En este derrotero exitoso, las propiedades antitumorales de la radioterapia fueron identificadas para el LH en 1902 y la curación de los estadios avanzados con esquemas de poliquimioterapia fue demostrada en 1964. En la década del 90, el tratamiento combinado de poliquimioterapia seguida de radioterapia mostró un incremento en las tasas de curación.
References
1. Graf S, Gopal A. Treatment of relapsed classical Hodgkin lymphoma in the brentuximab era. Hematology. 2014; 151-157.
2. Majhail NS, Weisdorf DJ, Defor TE et al. Long term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin´s lymphoma. Biol Blood Marrow Transplant. 2006; 12(10): 1065-1072.
3. Jethava Y, Murthy G, Hamadani M. Relapse of Hodgkin lymphoma after autologous transplantation. Time to rethink treatment? Hematol Oncol Stem Cell Ther. 2017; 10: 47-56.
4. Satwani P, Ahn KW, Carreras J et al. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Trasplant. 2015; 50: 1416-1423.
5. Martínez C, Canals C, Sarina B et al. Identification of prognostic factors predicting outcome in Hodgkin´s lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol. 2013; 24: 2430-2434.
6. Moskowitz CH, Nademanee A, Masszi T et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin´s lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 385: 1853-1862.
7. Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin´s lymphoma. J Clin Oncol. 2012; 30: 2183-2189.
8. Chen R, Gopal A, Smith S. Five year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016; 128 (12): 1562-1566.
9. Chen R, Palmer JM, Thomas SH et al. Brentuximab vedotin enables successful reduced intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012; 119 (26): 6379-6381.
10. Anderlini P, Saliba RM, Ledesma C et al. Reduced intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory Hodgkin lymphoma (HL) in the brentuximab vedotin era: favorable overall and progression free survival (OS/PFS) with low transplant related mortality (TRM). Blood. (ASH Annual Meeting Abstract) 2013; 122 (21): 410.
11. Garciaz S, Coso D, Peyrade F et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin´s lymphoma. Hematol Oncology. 2014; 32 (4): 187-191.
12. Armand P, Shipp MA, Ribrag V et al. Programmed death 1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuzimab vedotin failure. J Clin Oncol. 2016; 34 (31): 3733-3739.
13. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodkgin´s lymphoma. N Eng J Med. 2015; 372: 311-319.
14. Younes A, Santoro A, Shipp M et al. Nivolumab for classic Hodgkin lymphoma after autologous stem cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study. Lancet Oncol. 2016; 17(9): 1283-1294.
15. Armand P, Engert A, Younes A et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow up of the multicohort single arm phase II CheckMate 205 Trial. J Clin Oncol. 2018; 36(14): 1428-1439.
16. Chen R, Zinzani P, Fanale M et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for relapsed/refractory classic Hodgkin Lymphoma. J Clin Oncol. 2017; 35 (19): 2125-2132.
17. Cheson B, Ansell S, Schwartz L et al. Refinement of the Lugano classification response criteria for lymphoma in the era of immunomodulatory therapy. Blood. 2016; 128: 2489-2496.
18. Robinson SP, Sureda A, Canals C et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin´s lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009; 94 (2): 230-238.
19. Holmberg L, Maloney DG. The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma. J Natl Comp Canc Netw. 2011; 9 (9): 1060-1071.
20. Peggs KS, Hunter A, Chopra R et al. Clinical evidence of a graft versus Hodgkin´s lymphoma effect after reduced intensity allogeneic transplantation. Lancet. 2005; 365: 1934-1941.
21. Thompson KJ, Peggs KS, Smith P et al. Superiority of reduced intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin´s lymphoma following autologous stem cell transplantation. Bone Marrow Transplant. 2008; 41: 765-770.
22. Sureda A, Robinson S, Canals C et al. Reduced intensity conditioning compared with conventional allogeneic stem cell transplantation in relapsed or refractory Hodgkin´s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008; 26: 455-462.
23. Raiola A, Dominietto Am Varaldo R et al. Unmanipulated haploidentical BMT following non myeloablative conditioning and post transplantation CY for advanced Hodgkin´s lymphoma. Bone Marrow Transplant. 2014; 49 (2): 190-194.
24. Broder M, Quock T, Chang E et al. The cost of hematopoietic stem-cell transplantation in the United States. Am Health Drug Benefits. 2017; 10 (7): 366-374.
25. Mariotto AB, Yabroff KR, Shao Y et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103: 117-128.
26. Yalniz FF, Murad MH, Lee SJ et al. Steroid refractory chronic graft versus host disease: cost-effectiveness analysis. Biol Blood Marrow Trasplant. 2018; 14: 1920-1927.
2. Majhail NS, Weisdorf DJ, Defor TE et al. Long term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin´s lymphoma. Biol Blood Marrow Transplant. 2006; 12(10): 1065-1072.
3. Jethava Y, Murthy G, Hamadani M. Relapse of Hodgkin lymphoma after autologous transplantation. Time to rethink treatment? Hematol Oncol Stem Cell Ther. 2017; 10: 47-56.
4. Satwani P, Ahn KW, Carreras J et al. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Trasplant. 2015; 50: 1416-1423.
5. Martínez C, Canals C, Sarina B et al. Identification of prognostic factors predicting outcome in Hodgkin´s lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol. 2013; 24: 2430-2434.
6. Moskowitz CH, Nademanee A, Masszi T et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin´s lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 385: 1853-1862.
7. Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin´s lymphoma. J Clin Oncol. 2012; 30: 2183-2189.
8. Chen R, Gopal A, Smith S. Five year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016; 128 (12): 1562-1566.
9. Chen R, Palmer JM, Thomas SH et al. Brentuximab vedotin enables successful reduced intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012; 119 (26): 6379-6381.
10. Anderlini P, Saliba RM, Ledesma C et al. Reduced intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory Hodgkin lymphoma (HL) in the brentuximab vedotin era: favorable overall and progression free survival (OS/PFS) with low transplant related mortality (TRM). Blood. (ASH Annual Meeting Abstract) 2013; 122 (21): 410.
11. Garciaz S, Coso D, Peyrade F et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin´s lymphoma. Hematol Oncology. 2014; 32 (4): 187-191.
12. Armand P, Shipp MA, Ribrag V et al. Programmed death 1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuzimab vedotin failure. J Clin Oncol. 2016; 34 (31): 3733-3739.
13. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodkgin´s lymphoma. N Eng J Med. 2015; 372: 311-319.
14. Younes A, Santoro A, Shipp M et al. Nivolumab for classic Hodgkin lymphoma after autologous stem cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study. Lancet Oncol. 2016; 17(9): 1283-1294.
15. Armand P, Engert A, Younes A et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow up of the multicohort single arm phase II CheckMate 205 Trial. J Clin Oncol. 2018; 36(14): 1428-1439.
16. Chen R, Zinzani P, Fanale M et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for relapsed/refractory classic Hodgkin Lymphoma. J Clin Oncol. 2017; 35 (19): 2125-2132.
17. Cheson B, Ansell S, Schwartz L et al. Refinement of the Lugano classification response criteria for lymphoma in the era of immunomodulatory therapy. Blood. 2016; 128: 2489-2496.
18. Robinson SP, Sureda A, Canals C et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin´s lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009; 94 (2): 230-238.
19. Holmberg L, Maloney DG. The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma. J Natl Comp Canc Netw. 2011; 9 (9): 1060-1071.
20. Peggs KS, Hunter A, Chopra R et al. Clinical evidence of a graft versus Hodgkin´s lymphoma effect after reduced intensity allogeneic transplantation. Lancet. 2005; 365: 1934-1941.
21. Thompson KJ, Peggs KS, Smith P et al. Superiority of reduced intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin´s lymphoma following autologous stem cell transplantation. Bone Marrow Transplant. 2008; 41: 765-770.
22. Sureda A, Robinson S, Canals C et al. Reduced intensity conditioning compared with conventional allogeneic stem cell transplantation in relapsed or refractory Hodgkin´s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008; 26: 455-462.
23. Raiola A, Dominietto Am Varaldo R et al. Unmanipulated haploidentical BMT following non myeloablative conditioning and post transplantation CY for advanced Hodgkin´s lymphoma. Bone Marrow Transplant. 2014; 49 (2): 190-194.
24. Broder M, Quock T, Chang E et al. The cost of hematopoietic stem-cell transplantation in the United States. Am Health Drug Benefits. 2017; 10 (7): 366-374.
25. Mariotto AB, Yabroff KR, Shao Y et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103: 117-128.
26. Yalniz FF, Murad MH, Lee SJ et al. Steroid refractory chronic graft versus host disease: cost-effectiveness analysis. Biol Blood Marrow Trasplant. 2018; 14: 1920-1927.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar
Downloads
Download data is not yet available.